Most Popular Stories
- Debt payments still mire HCA
- Forum: IT won't help much until practices shift operations
- Cleveland Clinic lists potential conflicts of interest online
- A new strategy for harried physicians: See patients in groups
- Fitch changes not-for-profit hospital outlook to negative
- Rapid-response teams have little effect on cardiac arrest deaths
- Disruptive doctor behavior causes mistakes, intimidates workers
- AHA survey: Negative profit margins for hospitals
- DOD, VA move to SOA architecture to build interoperable systems
- HHS: 60 percent of DME companies banned by Medicare may keep billing
- Cleveland Clinic lists potential conflicts of interest online
- A new strategy for harried physicians: See patients in groups
Poll
Featured Jobs
-
California Internal Medicine
StaffPointe, LLC - near San Diego , CA -
Hawaii Gastroenterologist
StaffPointe, LLC - Honolulu , HI -
Maryland Nurse Practitioner CEx1159
StaffPointe, LLC - Prince Frederick County , MD -
Arkansas General Surgeon
StaffPointe, LLC - east central , AR -
Oregon Asst. Nurse Manager/Day Surgery
StaffPointe, LLC - Springfield , OR
Events
- Avaya Patient Payment Recovery Webinar
Thursday, December 11, 2008 1-2pm
Paid Research Reports
- Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
- Impact of Pharmacogenomics on Public Healthcare Policy
- The Cardiovascular Disorders Market Outlook to 2012
- 2008 Trends to Watch: Pharmaceutical Technology
- Pharmaceutical Pricing and Reimbursement: Strategies for market access across the US, Europe, Japan and other key geographies
Popular Topics
SPOTLIGHT: Outsiders should see FDA safety data
March 7, 2007 — 8:01pm ET
Some say that if outside researchers had access to drug safety data, disasters like the Vioxx scandal might have been avoided. At present, however, the FDA doesn't let outsiders see clinical trial data unless forced to do so. This secrecy can only do harm, suggests a new commentary in Health Affairs. Report
Be the first to comment
Related Stories
- Bill giving FDA more drug safety powers could pass
- Congress poised to give more power to the FDA
- FDA announces contracts for adverse events database
- FDA may get $275 million more for staff, outsourcing
- Merck agrees to $58M settlement on Vioxx ads
- Studies show problems with four big-name drugs
- Reports suggest that Merck downplayed Vioxx risks
- WellPoint, FDA collaborate on tracking drug safety
- ALSO NOTED: AIDS vaccine back at square one; What's behind the FDA's low drug approval rating?; and much more...
- ALSO NOTED: TN Medicaid to test e-prescribing program; NIH alerts patients of stolen personal information; and much more...
Comments
Post new comment
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site MapTHE FIERCEMARKETS NETWORKFierceFinance | FierceFinanceIT | FierceSarbox | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceBiotech | FierceBioResearcher | FiercePharma | FierceVaccines | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe© 2008 FierceMarkets, Inc. All rights reserved. |
![]() |





